Table 2.
Cost of erythropoiesis-stimulating agent (ESA) treatment and percentage savings associated with use of biosimilar epoetin α: fixed-dosing scenarios.
| ESA cost (€) |
Relative savings with use of biosimilar epoetin α 40,000 IU (%) |
Relative savings with use of biosimilar epoetin α 30,000 IU (%) |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scenario | Originator epoetin α | Epoetin β | Darbepoetin α QW | Darbepoetin α Q3W | Biosimilar epoetin α 40,000 IU | Biosimilar epoetin α 30,000 IU | Originator epoetin α | Epoetin β | Darbepoetin α QW | Darbepoetin α Q3W | Originator epoetin α | Epoetin β | Darbepoetin α QW | Darbepoetin α Q3W |
| Continuous standard dose | 5514 | 5684 | 6384 | 7093 | 4753 | 3564 | 13.8 | 16.4 | 25.5 | 33.0 | 35.4 | 37.3 | 44.2 | 49.7 |
| Sustained dose escalation (1.5×) | 7720 | 7957 | 8937 | 9930 | 6654 | 4990 | 13.8 | 16.4 | 25.5 | 33.0 | 35.4 | 37.3 | 44.2 | 49.7 |
| Discontinued dose escalation (1.5×) | 6065 | 6252 | 7022 | 7802 | 5228 | 3921 | 13.8 | 16.4 | 25.5 | 33.0 | 35.4 | 37.3 | 44.2 | 49.7 |
| Sustained dose escalation (2.0×) | 9925 | 10,231 | 11,490 | 12,767 | 8555 | 6416 | 13.8 | 16.4 | 25.5 | 33.0 | 35.4 | 37.3 | 44.2 | 49.7 |
| Discontinued dose escalation (2.0×) | 6617 | 6820 | 7660 | 8511 | 5703 | 4277 | 13.8 | 16.4 | 25.5 | 33.0 | 35.4 | 37.3 | 44.2 | 49.7 |
| Average | 7168 | 7389 | 8299 | 9221 | 6178 | 4643 | 13.8 | 16.4 | 25.5 | 33.0 | 35.4 | 37.3 | 44.2 | 49.7 |
QW, once weekly; Q3W, once every 3 weeks.